Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. (Q51763308)

11 April 2018

title

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. (English)

1 reference

11 April 2018

1 reference

Atsuo Tahara

1

1 reference

11 April 2018

Eiji Kurosaki

2

1 reference

11 April 2018

Masanori Yokono

3

1 reference

11 April 2018

Daisuke Yamajuku

4

1 reference

11 April 2018

Rumi Kihara

5

1 reference

11 April 2018

Yuka Hayashizaki

6

1 reference

11 April 2018

Toshiyuki Takasu

7

1 reference

11 April 2018

Masakazu Imamura

8

1 reference

11 April 2018

Li Qun

9

1 reference

11 April 2018

Hiroshi Tomiyama

10

1 reference

11 April 2018

Yoshinori Kobayashi

11

1 reference

11 April 2018

Atsushi Noda

12

1 reference

11 April 2018

Masao Sasamata

13

1 reference

11 April 2018

Masayuki Shibasaki

14

1 reference

11 April 2018

publication date

3 December 2011

1 reference

11 April 2018

Naunyn-Schmiedeberg's Archives of Pharmacology

published in

1 reference

11 April 2018

volume

385

1 reference

11 April 2018

page(s)

423-436

1 reference

11 April 2018

issue

4

1 reference

11 April 2018

https://scigraph.springernature.com/pub.10.1007/s00210-011-0713-z

exact match

0 references

cites work

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Diabetes control and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Quantitative determination of lactose, maltose, and sucrose in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Islet beta cell failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

The sodium/glucose cotransport family SLC5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0713-Z

Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family

21 January 2018

1 reference

12 December 2020

Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption

1 reference

12 December 2020

Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats

1 reference

12 December 2020

Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter

1 reference

12 December 2020

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes

1 reference

12 December 2020

On the Identity between the Small Intestinal Enzymes Phlorizin Hydrolase and Glycosylceramidase

1 reference

12 December 2020

Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

1 reference

12 December 2020

Renal Na(+)-glucose cotransporters

1 reference

12 December 2020

Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract

1 reference

12 December 2020

Sodium-glucose cotransporter inhibitors for diabetes

1 reference

12 December 2020

Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes

1 reference

12 December 2020

10.1007/S00210-011-0713-Z

Identifiers

DOI

1 reference

11 April 2018

PubMed ID

22139434

1 reference

11 April 2018